FDA cleared growth Hemosure has FDA-cleared products including the iFOB test and Accu-Reader A 100, signaling a credible, compliant platform with potential for expanded adoption across U.S. clinics and hospitals seeking automated occult blood testing solutions.

Automation advantage The Accu-Reader A 100 automates fecal occult blood testing and delivers results in about 5 minutes, presenting a compelling efficiency gain for labs and GI departments looking to increase throughput and reduce manual processing.

Regional accessibility Located near Los Angeles with proximity to major medical centers, Hemosure can target nearby hospital networks and regional distributors for quicker pilots, demonstrations, and contract opportunities.

Market position With the iFOB maintaining a top US position for a decade, there is a strong credibility signal to pursue expansion in private clinics, specialty GI practices, and urgent care networks seeking reliable occult blood testing options.

Growth financing cues Revenue range of 10–25 million indicates scale with room to grow; engage strategic partners or distributors in mid-market and international channels to accelerate adoption, leveraging existing tech stack familiarity for faster onboarding.